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Background: Enterovirus 71 (EV71) is major cause of hand, foot and mouth disease. Large epidemics of EV71
infection have been recently reported in the Asian-Pacific region. Currently, no vaccine is available to prevent
EV71 infection.
Results: The peptide (VP4N20) consisting of the first 20 amino acids at the N-terminal of VP4 of EV71 genotype C4
were fused to hepatitis B core (HBcAg) protein. Expression of fusion proteins in E. coli resulted in the formation of
chimeric virus-like particles (VLPs). Mice immunized with the chimeric VLPs elicited anti-VP4N20 antibody response.
In vitro microneutralization experiments showed that anti-chimeric VLPs sera were able to neutralize not only EV71
of genotype C4 but also EV71 of genotype A. Neonatal mice model confirmed the neutralizing ability of anti-chimeric
VLPs sera. Eiptope mapping led to the identification of a “core sequence” responsible for antibody recognition within
the peptide.
Conclusions: Immunization of chimeric VLPs is able to elicit antibodies displaying a broad neutralizing activity against
different genotypes of EV71 in vitro. The “core sequence” of EV71-VP4 is highly conserved across EV71 genotypes. The
chimeric VLPs have a great potential to be a novel vaccine candidate with a broad cross-protection against different
EV71 genotypes.
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Human enterovirus 71 is a non-enveloped RNA virus of
the Picornaviridae family. The virion is around 30 nm in
diameter containing a single-stranded positive-sense RNA
genome of approximately 7500 nucleotides [1-3]. The
whole genome is translated into a single large polyprotein
that can be subsequently processed by protease digestion to
produce four capsid subunit proteins, VP1 to VP4 and
other nonstructural proteins. The icosahedral capsid is
composed of 60 sets structural proteins (VP1 to VP4). It
has been shown that VP1-3 form a pseudo T = 3 icosahe-
dral capsid that are located on the surface of viral capsid
[4]. VP4 is located inside, which is approximately 70 amino
acids in length and is myristoylated at the N terminus [5,6].* Correspondence: sunxinbh@126.com; shengwang@bjut.edu.cn
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stated.Crystallographic analysis showed that the mature EV71
virus is structurally similar to other enteroviruses [7].
EV71 and coxsackievirus A16 (CA16) have been iden-
tified as the two major etiological agents of hand, foot
and mouth disease (HFMD) [8,9]. Large outbreaks of
HFMD have recently been reported in the Asia-Pacific
region, which is becoming a common acute viral disease
in these areas and posing a serious health threat to
children [10-13]. While HFMD is usually mild and
self-limiting, it may lead to severe neurological compli-
cations and even death [14,15]. However, no effective
vaccine is yet available to prevent EV71 infection.
The evidence that maternal mice vaccinated with the
EV71 virus-like particles (VLPs) can confer protection to
neonatal mice against lethal challenge reveals an essen-
tial role of neutralizing antibody in the protection
against infection [3]. To determine the immunodomi-
nant epitopes of EV71 capsid protein, antisera generated
from animals immunized with formalin-inactivated
EV71 vaccine were screened against a set of overlappingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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VP2 and VP3 of EV71. Several linear immunodominant
neutralization epitopes have been successfully identified
in VP1 and VP2 proteins [16-20]. Numerous studies re-
ported that synthetic peptides containing neutralizing
epitope of VP1 elicited neutralizing antibody response
and protected neonatal mice against lethal challenges
[17-20]. Therefore, the epitope-based vaccine has a great
potential to be a successful vaccine to prevent EV71
infection.
In the present study, the peptide consisting of N-
terminal residues 1–20 of EV71 VP4 of genotype C4
was fused to hepatitis B core antigen (HBcAg) and
expressed in E. coli. The resulting fusion proteins
were able to spontaneously assemble into chimeric
VLPs, which elicited virus-neutralizing antibody re-
sponse. We further identified a highly conserved linear
neutralizing epitope in the N-terminus of EV71 VP4 by
epitope mapping experiments. Our results suggest that
chimeric HBcAg particles carrying a neutralizing epi-
tope of EV71 VP4 could be a promising vaccine candi-
date against EV71 infection.Results
Generation of chimeric particles carrying the peptide
VP4N20
The gene sequence and amino acid sequence of peptide
VP4N20 as well as its insertion position in HBcAg are
shown in Figure 1. The plasmid vector pET22b (+)
(Novagen) encodes a six-histidine tag at the C-terminal
region of recombinant proteins for convenient purification
by affinity chromatography as well as expression analysis
by Western-blot. A carboxyl-terminally truncated HBcAgFigure 1 Schematic presentation of the chimeric HBcAg protein cons
and BrCr-TR. Italics letters indicate nucleotide sequences, and the percentag
from Asia.protein (149 aa, HBc-N149) and a fusion protein
(HBc-N149-VP4N20) were expressed in E. coli, respectively.
The efficient expression of both proteins was demon-
strated by Western-blot after IPTG induction (Figure 2A).
They were further purified using Ni Sepharose column.
The purity of proteins was evaluated by densitometric
analysis after staining with Coomassie blue and the repre-
sentative samples of expressed proteins were shown in
Figure 2B. Since HBcAg protein can form particles both
in vivo and in vitro, we then investigated whether the
recombinant proteins can form particles. Electron
microscopy analysis showed that both HBc-N149 and
HBc-N149-VP4N20 proteins were able to efficiently form
particles with the size around 25–30 nm (Figure 3). The
results suggest that the chimeric proteins can self-
assemble to form VLPs.
Chimeric particle immunization elicited VP4N20 specific
antibody responses in mice
To determine whether chimeric HBcAg particles were
capable of eliciting anti-VP4N20 antibody, female BALB/c
mice were immunized i.m. with either purified chimeric
VLPs (HBc-N149-VP4N20) or HBcAg VLPs (HBc-N149)
and received booster injections 3 weeks later. Mice immu-
nized with PBS were used as negative controls. The immu-
nized animals were bled at week 0, 2, 5, 8 for serological
analysis. The results showed that anti-VP4N20 antibody
became detectable in chimeric VLPs-immunized mice at
2 weeks after inoculation. The titers were enhanced by
booster injection and reached a maximum at week 5.
No anti-VP4N20 antibody response was detected in the
HBcAg VLPs -immunized group and the PBS group.
Our results indicated that chimeric particles were able
to induce anti-VP4N20 immune responses (Figure 4).truct. The shaded box represents the N-terminal 20 a.a. of VP4 of Bj08
es indicate the degree of conservation among the 100 strains of EV71
Figure 2 Protein expression and purification. The expression of HBc-N149 and HBc-N149-VP4N20 protein was detected by Western blot.
(A) Lane 1: HBc-N149-VP4N20. Lane 2: HBc-N149. Lane 3: Negative control. The protein purification was visualized by SDS-PAGE. (B) Lane 1:
Uninduced bacteria expressing HBc-N149-VP4N20; Lane 2: Induced bacteria expressing HBc-N149-VP4N20; Lane 3: Purified HBc-N149-VP4N20.
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antibodies against EV71
To evaluate whether the chimeric VLPs could induce
neutralizing antibodies against EV71, sera from immu-
nized mice were tested for the ability to neutralize live
EV71 in vitro. EV71 (genotype C4) and a variant of
the prototype strain of EV71, BrCr-TR (genotype A)
were used for in vitro neutralization assay. As shown
in Figure 5, the sera from the group immunized with
chimeric VLPs were able to neutralize EV71 (Bj08
strain) and prevented RD cells from developing cyto-
pathic effects. The highest neutralizing titre of around
1.36 × 102 was obtained at week 5 post-immunization
(Figure 6), which was consistent with the antibody
profile as shown in Figure 4. However, anti-chimeric
VLPs sera had a neutralizing activity against EV71 of
type A (BrCr-TR) with a neutralization titre similar toFigure 3 Electron microphotographs of HBc-N149 and HBc-N149-VP4
particles assembled from HBc-N149-VP4N20. Size bar: 50 nm.that against Bj08 strain (data not shown). Amino acid
sequence alignment show that the N-terminal sequence
of the Bj08 VP4 is identical to that of BrCr-TR (Figure 1).
Compared to chimeric particles, HBcAg particles failed
to induce neutralizing antibody responses against
EV71 (Bj08 strain) (Figure 5) as well as EV71 BrCr-TR
strain (data not shown). Our results indicate that
immunization of chimeric VLPs can elicit neutralizing
antibody responses against EV71 and the sera exhibit a
cross-neutralizing activity against EV71 strains belon-
ging to different genotypes in vitro.
Neonatal mice as a model to verify in vitro neutralizing
ability of chimeric VLP-immunized sera
EV71 BrCr-TR strain was used for viral infection be-
cause of its high virulence in neonatal mice. Groups of
one-day-old BALB/c suckling mice (n =10 per group)N20 particles. (A) Particles assembled from HBc-N149. (B) Chimeric
Figure 4 Kinetics of antibody titer development in mice
following immunization. Mice were immunized twice with 100 μl
preparation containing 5 μg of different proteins on week 0 and 3,
respectively, and were bled before immunization and at week 2, 5,
8 weeks after immunization for serological tests. BSA-VP4N20 was used
to coat EIA plates to detect VP4N20-specific antibodies. Each bar repre-
sents the mean reciprocal log10 endpoint titers and standard error.
Figure 5 Microneutralization assay results. The virus/antiserum mixtures
cells were observed to evaluate the appearance of cytopathic effects (CPEs
HBc-N149-VP4N20 sera. (C) EV71-infected cells. (D) EV71-bound cells were
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sera mixtures that had been incubated overnight at 37°C.
After 7 days, control mice receiving EV71 with either
PBS or anti- HBcAg VLPs sera started to show symp-
toms, such as reduced mobility, limb weakness, limb
paralysis, and death (Figure 7A and B). The survival
rates were 20% and 40% for the PBS and anti-HBcAg
VLPs sera recipient groups, respectively, at 16 day post-
inoculation (Figure 7C). In contrast, 90% of mice treated
with mixture of anti- chimeric VLPs sera remained
healthy and survived throughout the course. These ob-
servations confirmed previous experiments using RD
cells, that immune sera elicited by chimeric particles
neutralized EV71 infection.
Identification of “core sequence” by epitope mapping
VP4N20 peptide can elicit neutralizing antibody and
conferred cross-protection against EV71 strains belong-
ing to different genotypes in vitro. We further investi-
gated the most immunologically essential sequence of
the peptide by epitope mapping experiments to find out
the minimal peptide sequence showing the highest effi-
ciency for inducing the production of neutralizing anti-
body. A panel of peptides corresponding to the N- and
C-terminal truncations of VP4N20 peptide was used for
epitope mapping. As shown in Figure 8, the polyclonal
antibodies raised against the VP4N20 peptide were very
sensitive to truncation of either end of the peptide. Once
six (N-terminal) or ten (C-terminal) residues were clippedwere added into RD cells and incubated at 37°C. After 7 days, the
). (A) Uninfected cells. (B) EV71-bound cells were treated with the anti-
treated with the anti-HBc-N149 sera.
Figure 7 Neonatal mice as a model to assess in-vitro neutralizing effe
inoculated intraperitoneally (i.p.) with the virus-sera and virus-PBS mixture. (A)
EV71. The mouse on the left side received anti-chimeric VLPs sera and the on
paralysis in mouse is indicated by arrows. (B) Two representative mice in the
were recorded daily after infection for 16 days. 10 mice were used for each g
Figure 6 Kinetics of neutralizing antibodies to EV71 following
immunization. Neutralizing antibodies in the sera of immunized mice
to EV71 were measured by in vitro microneutralization assay. The
neutralizing antibody titer was defined as the highest serum dilution
that prevented the occurrence of cytopathic effects. Each bar
represents the mean reciprocal log2 endpoint titers and standard error.
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antibodies were no longer able to bind. One interpretation
of these results is that there is an essential “core” of the
peptide that does not tolerate truncation. The “core se-
quence” is highly conserved amongst the VP4 sequences
of EV71 strains from various genotypes based on the
alignment data (Figure 1). Our results suggest that
VP4N20 peptide may potentially elicit a pan-genotypic
immune response once the right segment of VP4 is
identified.
Discussion
Gene mutation and genetic recombination were fre-
quently observed during EV71 epidemics, resulting in
substantial genetic variation of EV71 genome and the
emergence of the various EV71 subgenotypes [21]. Virus
variants which possess a selective advantage in terms of
ability to evade host immune surveillance can spread
and become established within human populations. EV71
is classified into 11 subgenogroups according to the gen-
etic variation of VP1 gene [15]. EV71 genotype-related
HFMD outbreaks were extensively reported previously.
Genotype B1 was the major viral strain in circulation from
1970 to 1980 [22]. The co-circulation of four subgeno-
types C1, C2, B3, and B4 were observed in Malaysiacts of anti-sera. Groups of one-day-old BALB/c suckling mice were
Mice with different antiserum treatment at 11 days post-infection with
e on the right side received anti-HBcAg VLPs sera. The appearance of limb
PBS-treated group die at 7 days post-infection with EV71. (C) Survival rates
roup.
Figure 8 Effects of peptide length on recognition of VP4 peptides by antibodies raised against the first N-terminal 20 residues of EV71
VP4. The top panel shows the ELISA reaction of the polyclonal serum to peptides truncated at the carboxyl end of the 20-mer. The bottom
shows the same with the truncations at the amino end, and the highlighted yellow region shows the minimal apparent “core” of the peptide for
antibody recognition. The plus signs on the right of the diagram illustrate whether the polyclonal serum binds to the peptide fragment. OD450:
optical density at 450 nm.
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B5 were reported to be the circulating strains from 1998
to 2009 in Taiwan [22,23]. One exceptional case was ob-
served in China, where genotype C4 was identified as the
dominant viral strain responsible for the HFMD outbreak
from 2007–2011 [24,25]. Thus, an ideal vaccine should
elicit effective cross-neutralizing antibody responses
against different genotypes of EV71.
Several different types of EV71 vaccine candidates
have been investigated in animal model, including re-
combinant vaccines [3,26-28], peptide vaccines [19,20],
live attenuated vaccines [29,30] and formalin-inactivated
virion vaccines [31-34]. Only inactivated EV71 vaccines
are being evaluated in human clinical trials due to its su-
perior immunogenicity and more matured manufactu-
ring technologies. Inactivated EV71 virion vaccines have
been found to be able to elicit cross-neutralizing anti-
body responses against EV71 strains of different geno-
types in mouse model [34]. However, constant genetic
evolution has been observed in EV71 genome [35], the
efficiency of protective immunity elicited by currently
used inactivated EV71 virion vaccines against novel
EV71 variants thus still remain to be evaluated. Several
linear neutralizing epitopes have been identified in the
VP1 and VP2 proteins of EV71, which are very helpful
for detailed understanding of broad immunoprotection
elicited by inactivated EV71 virion vaccines and peptide-
based vaccine design [16,18-20].
Targeting conserved regions within the immunogens
for vaccine development is an alternative approach todeal with high genetic diversity of pathogens. EV71 VP4
gene is more conserved than VP1, VP2 and VP3 genes.
We therefore attempted to identify neutralization
epitopes in VP4 gene. We found that the first 20 N-
terminal amino acid residues are highly conserved
amongst the VP4 sequences of EV71 strains from various
genotypes. In the present study, the peptide consisting of
first 20 a.a. at N-terminal of VP4 of EV71 genotype C4
(VP4N20) was fused to HBcAg protein. HBcAg particles
have been extensively exploited as a carrier to improve
the immunogenicity of foreign protein segments pre-
sented on their surface. As expected, the fusion proteins
were able to assemble into chimeric VLPs in bacteria as
efficient as unmodified HBcAg. Immunization of the
chimeric VLPs was able to elicit VP4N20 specific anti-
body in mice. In vitro neutralization assay showed that
antibodies raised against chimeric VLPs were able to
not only neutralize EV71 of genotype C4 but also dis-
played a similar neutralizing activity against EV71 of
genotype A, indicating that immunization of the first
20 N-terminal amino acids of VP4 of EV71 genotype
C4 is able to elicit neutralizing antibody which exhibited
a broad neutralizing activity against different genotypes
of EV71 in vitro.
Neutralizing antibodies play an important role in the
immune defense against picornavirus infection. In the
case of poliovirus, antibodies raised against VP4 and the
N termini of VP1 of poliovirus serotype I were capable
of neutralizing the poliovirus virions [36,37]. Similar
results were reported in the studies on rhinovirus,
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successfully neutralize viral infectivity in vitro [38]. VP4
played a pivotal role during picornavirus cell entry des-
pite the fact that VP4 is buried in the interior of the cap-
sid at the capsid-RNA interface [39], indicating that the
picornavirus capsid structure is more dynamic than the
suggested crystal structure. It has been shown that the
attachment of picornavirus on the receptor can trigger
conformational alteration of virus and lead to the
externalization of VP4 and the N-terminus of VP1
[40,41]. The egress of the myristylated VP4 is involved in
the formation of channels responsible for the safe release
of the picornavirus genome to the cell cytoplasm [42].
The exposure of VP4 to the outside of the capsid may
potentially result in anti-VP4 antibody-mediated
neutralization against picornavirus. However, our re-
sults on neutralizing responses elicited by N-terminus
VP4 of EV71 are consistent with previous reports
[38,42]. Furthermore, we identified the “core sequence”
of N-terminus VP4 of EV71 responsible for antibody re-
cognition. The “core sequence” is highly conserved
amongst the VP4 sequences of EV71 strains from various
genotypes and that of CA16. Whether antibody responses
elicited by the N-terminus of EV71 VP4 are capable of
neutralizing CA16 virions still remains to be investigated.
Conclusions
In summary, this study identified an immunodominant epi-
tope located at the N-terminal of EV71 VP4 protein. The
fusion proteins of HBcAg and N-terminal of EV71 VP4-
derived peptide were able to spontaneously assemble into
chimeric VLPs. Mice immunization with these chimeric
VLPs elicited neutralizing antibodies against EV71 of
different genotypes. The “core sequence” responsible for
immune stimulation was found to be highly conserved
across different EV71 genotypes.
Methods
Plasmid constructions and bacterial strains
The peptide (VP4N20) that corresponds to first 20 resi-
dues at the N-terminal of VP4 of EV71 (Bj08) was inserted
to HBcAg (HBc-N149) loop region between amino acids
78 and 79. The fusion protein was named as HBc-N149-
VP4N20. To construct the plasmid expressing the fusion
protein, DNA fragment encoding HBc-N149-VP4N20 was
synthesized and amplified using primers P1u (5'-
CCGCTCGAGCACCACGGTGGTT-3') and P1d (5'-
GGAATTCCATATGGATATTGATCCGTATAAAG-3').
The PCR products were double-digested by XhoI and NdeI
and subsequently inserted into the vector pET22b(+)
(Novagen, USA). DNA fragment encoding HBc-N149 was
amplified by using the primers P1u, P2d (5′-TGGGCA
GCAATCTGGAAGATCCGGCGAGCCGCGAACTG-3′),
P2u (5′- ACCAGTTCGCGGCTCGCCGGATCTTCCAGATTGCTGCCCA-3′) and P1d by using HBc-N149-
VP4N20-encoding gene as a template and further inserted
into the vector pET22b (+). The accuracy of the constructs
was confirmed by sequencing. E. coli strain BL21 (DE3)
(BeiJing TIANGEN BIOTECH, China) were used for pro-
tein expression.
Expression and purification of recombinant proteins
Overnight cultures of BL21 (DE3) cells harboring the re-
combinant plasmids were diluted 1:400 in 1 L of LB
broth containing 100 μg/ml ampicillin, and grown until
reaching an OD600 of 0.4-0.6. Protein expression was
then induced by 0.1 mM of isopropyl-β-d-thiogalactopy-
ranoside (IPTG). After shaking at 37°C for 5 h, the bac-
teria were collected by centrifugation at 12,000 rpm for
10 min at 4°C, and the pellets were resuspended in 100 ml
of balance buffer (pH 8.0, 50 mM Tris, 100 mM NaCl,
10 mM imidazole). For protein purification, the bacterial
cells were lysed by ultrasonication, followed by centrifuga-
tion at 13,000 rpm for 15 min at 4°C to remove bacterial
debris. The clear supernatant was applied to a Ni Sephar-
ose column (GE Healthcare Life Sciences, USA) according
to the manufacturer’s recommendations. The columns
were washed with washing buffer (pH 8.0, 50 mM Tris–
HCl, 100 mM NaCl, 50 mM imidazole,) and bound pro-
teins were eluted with elution buffer (pH 8.0, 50 mM
Tris–HCl, 100 mM NaCl, 200 mM imidazole). The peak
fractions were collected and analyzed by SDS-PAGE. The
purity of the samples was determined by densitometric
scanning. The proteins were dialyzed to PBS buffer
(pH7.4) for 8 hours at RT and examined by electron mi-
croscopy and used for immunology studies.
SDS-PAGE and Western blotting
Electrophoresis was performed in 12% SDS polyacryl-
amide gels and the recombinant proteins were detected
by Western blotting using a monoclonal antibody (mAb)
against the polyhistidine (His) tag in the C-terminal re-
gion of the fusion protein. Briefly, the transferred PVDF
membrane was blocked with 2% (w/v) BSA in TBS for
1 h at 37°C, and washed thrice with TBS – 0.05% (v/v)
Tween 20, then the membrane was incubated with a
1:5,000 dilution of anti-His tag (mouse mAb, CWBIO,
Beijing, China) in a 0.2% BSA-TBS – 0.05% Tween 20
solution for 1 h at 37°C, and washed thrice with TBS –
0.05% Tween 20. Protein bands were probed with
1:2,000 dilution of HRP-conjugated goat anti-mouse IgG
(CWBIO, Beijing, China) and washed thrice as described
above. Chemiluminescence was applied as instructed
by the manufacturer (Li-COR Odyssey, USA).
Electron microscopy
The formation of HBcAg VLPs and chimeric VLPs (HBc-
N149-VP4N20) was analyzed by negative staining electron
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Briefly, proteins were adsorbed to 230 mesh carbon-
coated copper grids and incubated for 1 min. The grids
were then washed once with PBS and stained for 45 s with
2% phosphotungstic acid. Specimens were evaluated using
an electron microscope (H-7650, HITACHI, Japan).
Immunization of animals
Pathogen-free female BALB/c mice were purchased from
Beijing HFK Bioscience Co. (Beijing, China). All animals
were housed at pathogen-free conditions. Animal experi-
ments were performed in accordance with current guide-
lines for the Care and Use of Laboratory Animals of
Experimental Animal Center of Military Medical Sciences
and approved by the center. For mice experiments, five fe-
male BALB/c mice (6–8 weeks) per group were vaccinated
intramuscularly (i.m.) with recombinant proteins HBc-
N149 (5 μg/mouse) or HBc-N149-VP4N20 (5 μg/mouse)
at week 0. The second injection was performed at week 3.
QuickAntibody™ from KBQ Biotechnology Co. (Beijing,
China) was used as an adjuvant. Control group was im-
munized with PBS plus adjuvant. The immunized animals
were bled at week 0, 2, 5, 8 for antibody detection.
ELISA
Direct ELISA was used for detection of antibodies in the
sera of immunized animals. The peptide VP4N20 was
synthesized by Scilight-Peptide (Beijing, China) and con-
jugated with Bull Serum Albumin (BSA-VP4N20). The
peptides were purified using high-pressure liquid chro-
matography. ELISA plates (96-well) were coated with
250 ng/well of BSA-VP4N20 in coating buffer (50 mM
Na2CO3–NaHCO3, pH 9.6) overnight at 4°C. After
washing with PBS-0.05% (v/v) Tween 20 thrice, the
plates were blocked with 2% (w/v) BSA in PBS for 2 h at
37°C. Sera were tested at 2-fold serial dilutions starting
at 1:100. The plates were incubated at 37°C for 1 h and
washed thrice with PBS-0.05% Tween 20. HRP-
conjugated goat anti-mouse IgG (CWBIO, Beijing,
China) was then added into each well in a 1:2000 dilu-
tion, and incubated at 37°C for 1 h. The plates were
washed thrice and developed with TMB solution (Tiangen
Biotech, Beijing, China) in a dark room for 15 min, and
the enzyme reaction was stopped by adding 2 M H2SO4.
The absorbance at 450 nm was measured using a micro-
plate reader (Bio-Rad, USA).
Epitope mapping
Enzyme-linked immunosorbent assay (ELISA) protocols
were used for all the epitope mapping experiments. Pep-
tides truncated at the carboxyl end or the amino
terminus were purchased from Scilight-Peptide (Beijing,
China). The peptides were conjugated with Bull Serum
Albumin (BSA). The purity was higher than 90%.In vitro neutralization assay
EV71 BJ08 (genogroup C4) and BrCr-TR (genogroup A),
were propagated in RD cells. Virus titers were determined
using RD cells by the microtitration method and
expressed as the 50% tissue culture infective dose
(TCID50) according to the Reed–Muench method. Two-
fold serial dilutions of sera were prepared using Minimum
Essential Medium (MEM,Gibco®) containing 2% FBS. The
EV71 stock was diluted to a working concentration of 100
TCID50/50 μl. The neutralization assay was conducted
using 96-well plates. In each well, 50 μl of diluted serum
sample was mixed with 50 μl of EV71 at 100 TCID50, and
incubated overnight at 37°C. Next, 100 μl of cell suspen-
sion containing 10,000 RD cells was added to wells
containing the virus/antiserum mixtures and incubated at
37°C. After 7 days, the cells were observed to evaluate the
appearance of cytopathic effects. Neutralization titer was
defined as the highest serum dilution that could com-
pletely protect cells from developing cytopathic effects.
Mouse protection assay
To evaluate protective efficacy of the immunized sera
against EV71 infection, in vivo infection experiments were
performed. Briefly, 50 μl of sera or PBS were incubated
with 10 LD50 of EV71 BrCr-TR (50 μl in sterile RD cell
supernatant) at 37°C for 2 hour. Groups of one-day-old
BALB/c suckling mice (n = 10 per group) were inoculated
intraperitoneally (i.p.) with the virus-sera mixture or virus-
PBS mixture. All mice were monitored daily for clinical
symptoms and death for up to 16 days after inoculation.
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